Literature DB >> 2873863

Effect of somatostatin on renal function.

J P Vora, D R Owens, R Ryder, J Atiea, S Luzio, T M Hayes.   

Abstract

Somatostatin has profound effects on both splanchnic and portal vascular beds. The effects of intravenous somatostatin (100 micrograms/h) on urinary volume, effective renal plasma flow, and glomerular filtration rate were compared with the effects of a control infusion of physiological saline in six normal subjects. Renal plasma flow and glomerular filtration rate were measured by primed constant isotope infusions of iodine-125 iodohippurate and chromium-51 edetic acid. Urinary volume, renal plasma flow, and glomerular filtration rate were measured during 20 minute clearance periods. During the control infusion urinary volume, renal plasma flow, and glomerular filtration rate remained essentially unchanged at 254 (SEM 3) ml/20 min, 568 (5) ml/min/1.73 m2, and 110 (2) ml/min/1.73 m2 respectively. From similar basal values the infusion of somatostatin led to a rapid decrease in all three variables. After 120 minutes of infusion of somatostatin urinary volume, renal plasma flow, and glomerular filtration rate were reduced to 148 (17) ml/20 min (p less than 0.01), 422 (7) ml/min/1.73 m2 (p less than 0.001), and 93 (3) ml/min/1.73 m2 (p less than 0.05) respectively. This effect on renal function should be borne in mind whenever somatostatin is used.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2873863      PMCID: PMC1340632          DOI: 10.1136/bmj.292.6537.1701

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  14 in total

1.  Determination of total serum insulin (IRI) in insulin-treated diabetic patients.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1972-08       Impact factor: 10.122

2.  Glomerular filtration rate and renal plasma flow in short-term and long-term juvenile diabetes mellitus.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1971-09       Impact factor: 1.713

3.  Somatostatin and cimetidine in peptic-ulcer haemorrhage. A randomised controlled trial.

Authors:  L Kayasseh; K Gyr; U Keller; G A Stalder; M Wall
Journal:  Lancet       Date:  1980-04-19       Impact factor: 79.321

4.  Direct inhibition of gastric acid and pepsin secretion by growth-hormone release-inhibiting hormone in cats.

Authors:  A Gomez-Pan; J D Reed; M Albinus; B Shaw; R Hall
Journal:  Lancet       Date:  1975-04-19       Impact factor: 79.321

5.  Direct inhibition of gastric acid by growth-hormone release-inhibiting hormone in dogs.

Authors:  A A Barros D'Sa; S R Bloom; J H Baron
Journal:  Lancet       Date:  1975-04-19       Impact factor: 79.321

6.  Somatostatin and water excretion in man: an intrarenal action.

Authors:  B J Walker; P A Evans; M L Forsling; G A Nelstrop
Journal:  Clin Endocrinol (Oxf)       Date:  1985-08       Impact factor: 3.478

7.  Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.

Authors:  P Brazeau; W Vale; R Burgus; N Ling; M Butcher; J Rivier; R Guillemin
Journal:  Science       Date:  1973-01-05       Impact factor: 47.728

8.  Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men.

Authors:  J E Liljenquist; J D Bomboy; S B Lewis; B C Sinclair-Smith; P W Felts; W W Lacy; O B Crofford; G W Liddle
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

9.  The effect of short-term glucagon infusion on kidney function in normal man.

Authors:  H H Parving; J Noer; H Kehlet; C E Mogensen; P A Svendsen; L Heding
Journal:  Diabetologia       Date:  1977-08       Impact factor: 10.122

10.  Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus.

Authors:  J Wahren
Journal:  Lancet       Date:  1976-12-04       Impact factor: 79.321

View more
  10 in total

Review 1.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.

Authors:  A Lianne Messchendorp; Edwin M Spithoven; Niek F Casteleijn; Wendy A Dam; Jacob van den Born; Wouter F Tonnis; Carlo A J M Gaillard; Esther Meijer
Journal:  BMC Nephrol       Date:  2018-12-19       Impact factor: 2.388

3.  Effect of somatostatin on kidney function and vasoactive hormone systems in health subjects.

Authors:  T Tulassay; Z Tulassay; W Rascher; L Szücs; H W Seyberth; I Nagy
Journal:  Klin Wochenschr       Date:  1991-08-01

4.  Practice guidance for the use of terlipressin for liver cirrhosis-related complications.

Authors:  Xingshun Qi; Zhaohui Bai; Qiang Zhu; Gang Cheng; Yu Chen; Xiaowei Dang; Huiguo Ding; Juqiang Han; Lei Han; Yingli He; Fanpu Ji; Hongxu Jin; Bimin Li; Hongyu Li; Yiling Li; Zhiwei Li; Bang Liu; Fuquan Liu; Lei Liu; Su Lin; Dapeng Ma; Fanping Meng; Ruizhao Qi; Tianshu Ren; Lichun Shao; Shanhong Tang; Yufu Tang; Yue Teng; Chunhui Wang; Ran Wang; Yunhai Wu; Xiangbo Xu; Ling Yang; Jinqiu Yuan; Shanshan Yuan; Yida Yang; Qingchun Zhao; Wei Zhang; Yongping Yang; Xiaozhong Guo; Weifen Xie
Journal:  Therap Adv Gastroenterol       Date:  2022-05-18       Impact factor: 4.802

Review 5.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

6.  Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.

Authors:  Katharina Hopp; Cynthia J Hommerding; Xiaofang Wang; Hong Ye; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 10.121

7.  Reduction of the effluent volume in high-output ileostomy patients by a somatostatin analogue, SMS 201-995.

Authors:  K Kusuhara; M Kusunoki; T Okamoto; Y Sakanoue; J Utsunomiya
Journal:  Int J Colorectal Dis       Date:  1992-12       Impact factor: 2.571

8.  Hemodynamic effects of somatostatin in the rat: relationship with plasma glucagon levels.

Authors:  J M Romeo; C Novo; A Fernández-Cruz; J M Lòpez-Novoa
Journal:  Heart Vessels       Date:  1990       Impact factor: 2.037

Review 9.  Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance.

Authors:  J C Reubi; J C Schaer; R Markwalder; B Waser; U Horisberger; J Laissue
Journal:  Yale J Biol Med       Date:  1997 Sep-Dec

10.  Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD.

Authors:  A Lianne Messchendorp; Bart J Kramers; Edwin M Spithoven; Katrin Stade; Esther Meijer; Ron T Gansevoort
Journal:  Kidney Int Rep       Date:  2019-05-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.